Onconetix, Inc. (ONCO)
NCM · Healthcare · Biotechnology
Closing price as of 2026-07-30 · Source: TEK2day Finance
Key Metrics
About Onconetix, Inc.
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 106K | 304K | 304K | 21K |
| Gross Profit | 71K | 269K | 248K | -2K |
| Operating Income | -1.3M | -2.1M | -1.3M | -2.1M |
| Net Income | -2.4M | -8.8M | 5.7M | -4.2M |
| Diluted EPS | $-238.00 | $-312.50 | $nan | $-67.10 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 58K | 2.5M | 815K |
| Gross Profit | 0.00 | -1.1M | 1.1M | 633K |
| Operating Income | -13.5M | -17.8M | -10.3M | -6.3M |
| Net Income | -13.4M | -37.4M | -58.7M | -14.0M |
| Diluted EPS | $-151,867.29 | $-285,570.18 | $-21,301.06 | $-828.00 |